Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06379360
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-18
Brief Title:
Maintenance Therapy of Hypomethylating Agent HMA in Favorable Risk Acute Myeloid Leukemia AML Patients
Sponsor:
The First Affiliated Hospital of Soochow University
Organization:
The First Affiliated Hospital of Soochow University
Study Overview
Official Title:
Maintenance Therapy of Hypomethylating Agent HMA in Favorable Risk Acute Myeloid Leukemia AML Patients A Single Arm Multi Center Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HMA maintenance therapy is expected to benefit overall survival OS and relapse free survival RFS in AML patients with favorable risk
Detailed Description:
Applying hypomethylating agents azacitidine or decitabine as maintenance therapy in favorable-risk AML may prolong the remission duration and further improve their long-term survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None